Improving treatment of non-Hodgkin lymphoma (NHL) through pretargeted radioimmunotherapy (PT-RIT) and consolidation veltuzumab (humanized anti-CD20) IgG serotherapy

被引：0
|
作者：
Sharkey, R. M. [1 ,2 ]
Karacay, H. [1 ,2 ]
Johnson, C. R. [1 ,2 ]
Rossi, E. A. [3 ]
McBride, W. J. [4 ]
Chang, C-H [3 ,4 ]
Goldenberg, D. M. [1 ,2 ,3 ,4 ]
机构：
[1] Ctr Mol Med & Immunol, Belleville, NJ USA
[2] Garden State Canc Ctr, Belleville, NJ USA
[3] IBC Pharmaceut Inc, Morris Plains, NJ USA
[4] Immunomedics Inc, Morris Plains, NJ USA
来源：
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS | 2008年 / 23卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
26
引用
收藏
页码：521 / 521
页数：1
相关论文
共 50 条
  • [41] Phase I/II trial epratuzumab (humanized anti-CD22 antibody) in non-Hodgkin's lymphoma (NHL).
    Leonard, JP
    Coleman, M
    Matthews, JC
    Chadburn, A
    Wegener, WA
    Hansen, HJ
    Ziccardi, H
    Kapushoc, H
    Gayko, U
    Cesano, A
    Fields, SZ
    Goldenberg, DM
    BLOOD, 2002, 100 (11) : 358A - 358A
  • [42] Anti-CD45 monoclonal antibody (MAb) dose optimization for astatine-211 (211At) -radioimmunotherapy (RIT) of relapsed non-Hodgkin lymphoma (NHL) in a canine model
    Frost, Sofia
    Miller, Brian
    Back, Tom
    Santos, Erlinda
    Hamlin, Donald
    Press, Oliver
    Storb, Rainer
    Wilbur, D. Scott
    Sandmaier, Brenda
    Pagel, John
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55
  • [43] Therapy of refractory non-Hodgkin's lymphoma (NHL) with 131I-LL2 (anti-CD22) radioimmunotherapy (RIT):: Results of a repetitive dosing trial.
    Vose, J
    Colcher, D
    Bierman, P
    Gobar, L
    Hohenstein, M
    Augustine, S
    Goldenberg, D
    Tempero, M
    Armitage, J
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 1998, 13 (01) : 65 - 65
  • [44] Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma:: Safety and efficacy of re-treatment
    Davis, TA
    Grillo-López, AJ
    White, CA
    McLaughlin, P
    Czuczman, MS
    Link, BK
    Maloney, DG
    Weaver, RL
    Rosenberg, J
    Levy, R
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) : 3135 - 3143
  • [45] IDEC-Y2B8 (90)yttrium anti-CD20 radioimmunotherapy of relapsed non-Hodgkin's lymphoma (NHL): Interim results of a Phase I/II trial.
    Witzig, T
    Wiseman, C
    White, CA
    Solinger, A
    Gordon, L
    Raubitschek, A
    Emmanoulides, C
    Royston, I
    Parker, E
    Chinn, P
    GrilloLopez, A
    BLOOD, 1997, 90 (10) : 2606 - 2606
  • [46] Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma
    Chinn, PC
    Leonard, JE
    Rosenberg, J
    Hanna, N
    Anderson, DR
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1999, 15 (05) : 1017 - 1025
  • [47] Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma
    Stein, R
    Qu, ZX
    Chen, S
    Rosario, A
    Shi, V
    Hayes, M
    Horak, ID
    Hansen, HJ
    Goldenberg, DM
    CLINICAL CANCER RESEARCH, 2004, 10 (08) : 2868 - 2878
  • [48] Targeted anti-cancer therapy using a chimeric anti-CD20 antibody in the treatment of non-Hodgkin's B cell lymphoma
    Anderson, DR
    Varns, C
    IMMUNOLOGY, 1996, 89 : SI112 - SI112
  • [49] Anti-CD20 monoclonal antibody (rituximab) associated to mine and autotransplantation in patients with relapsed or primary refractary follicular or transformed follicular non-Hodgkin lymphoma (NHL).
    Solano, C
    Gutiérrez, AM
    Benet, I
    Marugán, I
    Tormo, M
    Terol, MJ
    Prósper, F
    García-Conde, J
    BLOOD, 1999, 94 (10) : 406B - 406B
  • [50] Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody
    Tsai, DE
    Maillard, I
    Schuster, SJ
    Nasta, SD
    Porter, DL
    Klumpp, TR
    Goldenberg, DM
    Luger, SM
    Alavi, A
    Sharkey, RM
    Hartzell, KB
    Stadtmauer, EA
    CLINICAL LYMPHOMA, 2003, 4 (01): : 56 - 59
12345